Not only do we represent a significant turnover, but often Europe is the trendsetter in terms of new products and procedures [for Nipro]. In this regard,…
In Conversation
Now the question is, looking forward, how are we going to ensure these shortages do not happen again and who should pay for it? There needs…
Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers in this area
Fundamentally, we are convinced that the China ophthalmology market is still a relatively blank slate with huge potential for innovative therapies and drugs, compared to the…
By now, we have a platform of over 500 billion small molecules, and in terms of published numbers, we probably have the largest DEL collections in…
When the already-high levels of motivation and engagement among our employees were combined with the additional sense of purpose and urgency that COVID-19 has brought, our…
The pandemic, while tragic, has provided Korean bio-ventures with opportunities to develop and mature
In Benelux there is probably not a single person who has never been in contact with a BD solution. Mathematically, we touch more than 20 patients…
Finding the unique algorithm specifically engineered for pre-menopausal Asian [breast cancer] patients was an important step for us and was crucial in confirming the accuracy of…
Here in Belgium, we have a perfect match between country and company, as both thrive on innovation
Recently we have patented the new MMCR technology (for multi-layer microparticle controlled-release system) enabling us to convert a well-established API from tablets to syrup, with the…
I predict that some of the changes in consumer preferences will remain after the pandemic ends. Therefore, we as an organisation need to be ready for…
